This phase I, prospective, two period, fixed sequence study will investigate the pharmacokinetics (PK), glucodynamics (GD), safety, and tolerability of Insulin peglispro [LY2605541] in healthy volunteers

Trial Profile

This phase I, prospective, two period, fixed sequence study will investigate the pharmacokinetics (PK), glucodynamics (GD), safety, and tolerability of Insulin peglispro [LY2605541] in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs Insulin peglispro (Primary) ; Insulin peglispro
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top